title: Myeloproliferative Neoplasms: Molecular Drivers and Therapeutics.
abstract: Activating mutations in genes that drive neoplastic cell growth are numerous and widespread in cancer, and specific genetic alterations are associated with certain types of cancer. For example, classic myeloproliferative neoplasms (MPNs) are hematopoietic stem cell disorders that affect cells of the myeloid lineage, including erythrocytes, platelets, and granulocytes. An activating mutation in the JAK2 tyrosine kinase is prevalent in these diseases. In MPN patients that lack such a mutation, other genetic changes that lead to activation of the JAK2 signaling pathway are present, indicating deregulation of JAK2 signaling plays an etiological driving role in MPNs, a concept supported by significant evidence from in vivo experimental MPN systems. Thus, small molecules that inhibit JAK2 activity are ideal drugs to impede the progression of disease in MPN patients. However, even though JAK inhibitors provide significant symptomatic relief, they have failed as a remission-inducing therapy. Nonetheless, the progress made understanding the molecular etiology of MPNs since 2005 is significant and has provided insight for the development and testing of novel molecular targeted therapeutic approaches. The current understanding of driver mutations in MPNs and an overview of current and potential therapeutic strategies for MPN patients will be discussed.
authors.affiliation: H. Lee Moffitt Cancer Center, Tampa, FL, United States; University of South Florida, Tampa, FL, United States. Electronic address: gary.reuther@moffitt.org.
authors.forename: G W
authors.initials: GW
authors.lastname: Reuther
mesh_terms: D000818:Animals; D006801:Humans; D058990:Molecular Targeted Therapy; D009154:Mutation / Q000235:genetics; D009196:Myeloproliferative Disorders / Q000235:genetics* / Q000628:therapy*; D015398:Signal Transduction / Q000235:genetics
keywords: CALR; JAK2; JAK2-V617F; Kinase; Leukemia; MPL; MPN; Targeted therapy